This is in line with public sequencing data from The Cancer Genome Atlas (TCGA), which showed neither mutation nor amplification of PPP4R2 but deletion in 1.6% of AML cases [3]. The gene discussed is PPP4R2; the disease is acute myeloid leukemia.